Douglas J. Jolly
YOU?
Author Swipe
View article: Supplementary Figure, Table & Dataset legends from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Supplementary Figure, Table & Dataset legends from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Supplementary Figure, Table & Dataset legends
View article: Figure S4 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S4 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S4
View article: Table S1 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Table S1 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Tg 511-11-01 (Study 11) dosing table.
View article: Figure S5 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S5 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S5
View article: Figure S8 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S8 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S8
View article: Figure S1 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S1 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S1
View article: Figure S9 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S9 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S9
View article: Figure S12 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S12 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S12
View article: Figure S2 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S2 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S2
View article: Supplementary Material from Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma
Supplementary Material from Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma Open
Supplementary Figures S1 to S9 and Supplementary Table S1.
View article: Figure S7 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S7 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S7
View article: Figure S3 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S3 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S3
View article: Figure S4 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S4 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S4
View article: Figure S6 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S6 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S6
View article: Table S2 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Table S2 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Tg 511-13-01 (Study 13) dosing table.
View article: Figure S5 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S5 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S5
View article: Text S1 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Text S1 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Supplementary Text
View article: Dataset S1 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Dataset S1 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Toca 511 qPCR detection results
View article: Data from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Data from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Purpose: Toca 511 is a gammaretroviral replicating vector encoding cytosine deaminase that selectively infects tumor cells and converts the antifungal drug 5-fluorocytosine into the antineoplastic drug 5-fluorouracil, which directly kills …
View article: Text S1 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Text S1 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Supplementary Text
View article: Table S1 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Table S1 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Tg 511-11-01 (Study 11) dosing table.
View article: Figure S6 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S6 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S6
View article: Data from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Data from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Purpose: Toca 511 is a gammaretroviral replicating vector encoding cytosine deaminase that selectively infects tumor cells and converts the antifungal drug 5-fluorocytosine into the antineoplastic drug 5-fluorouracil, which directly kills …
View article: Figure S8 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S8 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S8
View article: Figure S10 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S10 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S10
View article: Figure S2 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S2 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S2
View article: Figure S10 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Figure S10 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Figure S10
View article: Data from Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma
Data from Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma Open
Purpose:High-grade gliomas (HGGs) are central nervous system tumors with poor prognoses and limited treatment options. Vocimagene amiretrorepvec (Toca 511) is a retroviral replicating vector encoding cytosine deaminase, which converts exte…
View article: Supplementary Material from Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma
Supplementary Material from Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma Open
Supplementary Figures S1 to S9 and Supplementary Table S1.
View article: Dataset S1 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Dataset S1 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients Open
Toca 511 qPCR detection results